Steven Lichtman

Stock Analyst at Oppenheimer

(3.17)
# 1,030
Out of 4,853 analysts
66
Total ratings
44.68%
Success rate
14.49%
Average return

Stocks Rated by Steven Lichtman

Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312$324
Current: $317.16
Upside: +2.16%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115$105
Current: $85.74
Upside: +22.46%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145$135
Current: $91.92
Upside: +46.87%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10$12
Current: $4.30
Upside: +179.07%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103$110
Current: $86.93
Upside: +26.54%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92$94
Current: $87.00
Upside: +8.05%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72$65
Current: $14.90
Upside: +336.24%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47$58
Current: $20.66
Upside: +180.80%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10$11
Current: $10.60
Upside: +3.77%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.96
Upside: +9.49%
Maintains: Outperform
Price Target: $82$87
Current: $95.13
Upside: -8.55%
Maintains: Perform
Price Target: $58$68
Current: $102.83
Upside: -33.87%
Reiterates: Outperform
Price Target: $3.5
Current: $0.81
Upside: +332.10%
Maintains: Perform
Price Target: $273$288
Current: $383.10
Upside: -24.82%
Downgrades: Perform
Price Target: $105
Current: $92.69
Upside: +13.28%
Initiates: Perform
Price Target: $150
Current: $17.39
Upside: +762.56%
Maintains: Perform
Price Target: $83$85
Current: $71.18
Upside: +19.42%